Quantcast

Latest Immunosuppressive agents Stories

2009-04-09 03:43:00

JAKARTA, Indonesia, April 9 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life. (Logo:...

2009-04-06 03:24:00

MANILA, Philippines, April 6 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life. In the Philippines, Serologic...

2009-03-31 22:40:00

KUALA LUMPUR, Malaysia, March 31 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life. (Logo:...

2008-11-03 09:00:06

ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem(R) or 2- methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School of Medicine at UCLA, were...

2008-10-21 12:00:08

Ariad Pharmaceuticals, a developer of medicines to treat cancer, has announced the initiation of a Phase II clinical trial by Merck & Co to evaluate the safety and efficacy of oral deforolimus, Ariad's investigational mTOR inhibitor, in patients with advanced prostate cancer. In collaboration with Merck, deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different types of cancer. Under the...

2008-10-17 03:00:16

Lund, Sweden, October 17, 2008 - Active Biotech AB's (NASDAQ OMX Nordic: ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) today announce information regarding the candidate drug RhuDex(R) for the treatment of rheumatoid arthritis. RhuDex(R) will be examined in a further series of laboratory tests, under the auspices of the UK MHRA (Medicines and Healthcare products Regulatory Agency). These in-vitro studies will examine any potential detrimental interactions between...

2008-10-16 15:00:09

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new data from clinical and preclinical studies evaluating the company's investigational small molecule cancer therapies - its mTOR inhibitor deforolimus, and its multi-targeted kinase inhibitor AP24534 - will be presented during the 20th Annual EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer Therapeutics," being held in Geneva, Switzerland from October 21 through October 24, 2008. The schedule of...

2008-10-10 09:00:52

Biogen Idec, a US-based pharmaceutical company, has announced that its Phase II trial of baminercept in rheumatoid arthritis patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug did not meet its primary endpoint. The primary endpoint was defined as the proportion of baminercept-treated patients who achieved an ACR50 response, a standard measure of disease improvement in rheumatoid arthritis (RA), compared to placebo at 14 weeks....

2008-10-09 18:00:37

Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept (BG9924, LT(beta)R-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint. The primary endpoint was defined as the proportion of baminercept-treated patients who achieved an ACR50 response, a standard measure of disease improvement in RA, compared to placebo at 14 weeks. The study...

2008-09-19 12:00:36

Teva Pharmaceutical Industries has reported new data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis, which demonstrated a significant reduction in the mean number of gadolinium-enhancing lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose. In relapsing-remitting multiple sclerosis patients who switched from placebo to laquinimod, 52% reduction in the mean number of GdE lesions...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related